VENCLEXTA (venetoclax) Phase III studies in AML
~6 mins
We are pleased to share this video where Dr Vinod Pullarkat from the City of Hope National Medical Center, California, US, discusses some of the key efficacy and safety data from the pivotal VENCLEXTA acute myeloid leukaemia (AML) clinical trials VIALE-A and VIALE-C.
VIALE-A: A randomised, double-blind, placebo controlled phase 3 study that evaluated the efficacy and safety of VENCLEXTA in combination with azacitidine versus placebo in combination with azacitidine in patients with newly diagnosed AML who were ineligible for intensive chemotherapy.1,2 VIALE-C: A randomised double-blind placebo-controlled phase 3 study that evaluated VENCLEXTA in combination with LDAC versus placebo in combination with LDAC in newly diagnosed patients with AML who were ineligible for intensive chemotherapy.2,3
YOU MIGHT ALSO BE INTERESTED IN...
VENCLEXTA in AML:
An Australian Perspective
~6 mins
AML management:
An introduction to VENCLEXTA
~3 mins
VENCLEXTA in AML:
Management & mitigation strategies
~5 mins
Contact
Discover more about how we can help you in your practice.
PBS Information
Venclexta: VENCLEXTA (venetoclax) in combination with rituximab is PBS listed for relapsed or refractory chronic lymphocytic leukaemia (CLL). VENCLEXTA in combination with obinutuzumab is PBS listed for first line treatment of CLL or small lymphocytic lymphoma (SLL). VENCLEXTA in combination with azacitidine is PBS listed for treatment of acute myeloid leukaemia (AML). General Schedule listing. Authority required (telephone). Refer to PBS schedule for full authority information. VENCLEXTA monotherapy is not listed on the PBS. VENCLEXTA in combination with low-dose cytarabine is not listed on the PBS for treatment of AML.
Please review the full Product Information (PI) before prescribing, available below.
AML: acute myeloid leukaemia; LDAC: low-dose cytarabine.
References: 1. DiNardo CD, et al. N Engl J Med. 2020;383(7):617-629. 2. VENCLEXTA Product Information. 3. Wei AH, et al. Blood. 2020;135(24):2137-2145.
AU-VENA-210111 September 2022